These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31709525)

  • 21. CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability.
    Nozaki Y; Honda Y; Watanabe H; Saiki S; Koyabu K; Itoh T; Nagasawa C; Nakamori C; Nakayama C; Iwasaki H; Suzuki S; Washio I; Takahashi E; Miyamoto K; Yamanishi A; Endo H; Shinozaki J; Nogawa H; Kunimatsu T
    Regul Toxicol Pharmacol; 2016 Jun; 77():75-86. PubMed ID: 26884090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro-arrhythmia Assay initiative studies.
    Ligneau X; Shah RR; Berrebi-Bertrand I; Mirams GR; Robert P; Landais L; Maison-Blanche P; Faivre JF; Lecomte JM; Schwartz JC
    Br J Pharmacol; 2017 Dec; 174(23):4449-4463. PubMed ID: 28941245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uncertainty Quantification Reveals the Importance of Data Variability and Experimental Design Considerations for
    Chang KC; Dutta S; Mirams GR; Beattie KA; Sheng J; Tran PN; Wu M; Wu WW; Colatsky T; Strauss DG; Li Z
    Front Physiol; 2017; 8():917. PubMed ID: 29209226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel.
    Crumb WJ; Vicente J; Johannesen L; Strauss DG
    J Pharmacol Toxicol Methods; 2016; 81():251-62. PubMed ID: 27060526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 13th Annual Meeting of the Safety Pharmacology Society: focus on novel technologies and safety pharmacology frontiers.
    Cavero I
    Expert Opin Drug Saf; 2014 Sep; 13(9):1271-81. PubMed ID: 25054438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.
    Farkas AS; Nattel S
    Drugs; 2010 Mar; 70(5):573-603. PubMed ID: 20329805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative.
    Huang H; Pugsley MK; Fermini B; Curtis MJ; Koerner J; Accardi M; Authier S
    J Pharmacol Toxicol Methods; 2017 Sep; 87():11-23. PubMed ID: 28408211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prospective IQ-CSRC trial: A prototype early clinical proarrhythmia assessment investigation for replacing the ICH E14 thorough QTc (TQT) study.
    Cavero I; Holzgrefe H; Clements M
    J Pharmacol Toxicol Methods; 2016; 80():1-8. PubMed ID: 26903171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias.
    Blinova K; Stohlman J; Vicente J; Chan D; Johannesen L; Hortigon-Vinagre MP; Zamora V; Smith G; Crumb WJ; Pang L; Lyn-Cook B; Ross J; Brock M; Chvatal S; Millard D; Galeotti L; Stockbridge N; Strauss DG
    Toxicol Sci; 2017 Jan; 155(1):234-247. PubMed ID: 27701120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Electrocardiographic biomarkers to confirm drug's electrophysiological effects used for proarrhythmic risk prediction under CiPA.
    Vicente J; Hosseini M; Johannesen L; Strauss DG
    J Electrocardiol; 2017; 50(6):808-813. PubMed ID: 28928044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Introduction to
    Park JS; Jeon JY; Yang JH; Kim MG
    Transl Clin Pharmacol; 2019 Mar; 27(1):12-18. PubMed ID: 32055576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimization of an
    Dutta S; Chang KC; Beattie KA; Sheng J; Tran PN; Wu WW; Wu M; Strauss DG; Colatsky T; Li Z
    Front Physiol; 2017; 8():616. PubMed ID: 28878692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti-seizure medication: Levetiracetam case study.
    Delaunois A; Mathy FX; Cornet M; Gryshkova V; Korlowski C; Bonfitto F; Koch J; Schlit AF; Hebeisen S; Passini E; Rodriguez B; Valentin JP
    Pharmacol Res Perspect; 2023 Feb; 11(1):e01059. PubMed ID: 36748725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [hiPSCs and organoids: prediction of arrhythmogenic risks for optimized traditional Chinese medicine].
    Sun HK; Gao Y; Zhu MJ; Tang JF; Wu Y; Li B; Yu R; Wang Y; Zhou LY
    Zhongguo Zhong Yao Za Zhi; 2023 Oct; 48(20):5404-5409. PubMed ID: 38114134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety pharmacology methods and models in an evolving regulatory environment.
    Pugsley MK; de Korte T; Authier S; Huang H; Accardi MV; Curtis MJ
    J Pharmacol Toxicol Methods; 2017 Sep; 87():1-6. PubMed ID: 28461240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Occurrence of early afterdepolarization under healthy or hypertrophic cardiomyopathy conditions in the human ventricular endocardial myocyte: In silico study using 109 torsadogenic or non-torsadogenic compounds.
    Christophe B
    Toxicol Appl Pharmacol; 2022 Mar; 438():115914. PubMed ID: 35150662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs.
    Vicente J; Stockbridge N; Strauss DG
    J Electrocardiol; 2016; 49(6):837-842. PubMed ID: 27524478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In silico assessment on TdP risks of drug combinations under CiPA paradigm.
    Qauli AI; Marcellinus A; Setiawan MA; Zain AFN; Pinandito AM; Lim KM
    Sci Rep; 2023 Feb; 13(1):2924. PubMed ID: 36807374
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of disease state on arrhythmic event detection by action potential modelling in cardiac safety pharmacology.
    Christophe B; Crumb WJ
    J Pharmacol Toxicol Methods; 2019; 96():15-26. PubMed ID: 30580044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology.
    Li Z; Dutta S; Sheng J; Tran PN; Wu W; Chang K; Mdluli T; Strauss DG; Colatsky T
    Circ Arrhythm Electrophysiol; 2017 Feb; 10(2):e004628. PubMed ID: 28202629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.